Leading a team of finance professionals across R&D and Product Development & Supply (PDS) Finance in the interface between Finance and Business. Ensure delivery of the recurrent operational tasks: budget, closing of month/quarter, long range plan etc, while supporting decision making in R&D and PDS. Reporting to the head of Group Finance, and member of the R&D and PDS leadership teams.

Lead the R&D Finance and Portfolio Valuation team(*) Business partner for the head of R&D, and supporting the head of Group Finance and the CFO.(*) Recurrent operational tasks: budget, closing of month/quarter, long range plan etc(*) Support decision making for later stage R&D projects(*) Member of the R&D leadership team

Headed a the team of Partnering Commercial Assessment Leaders in providing assessment/valuation and strategic context for decision making clinical stage on Licensing and M&A opportunities - in the interface of business development, commercial and R&D. This involves due diligence, understanding the market (or what it would take to build it), building the market outlook/ revenue forecast for the opportunity, modelling development plans' cost and risk, and helping the BD project leader and deal team around modelling/negotiation of terms.Strategy development and aligning with the commercial organization. As part of Global Product Strategy's Portfolio Strategy team work on strategy development, and creating connectivity to the commercial organization. Help the Global Product Strategy Leadership with prioritization across disease areas.

Group Strategic Planning in Corporate Finance: Modelling of R&D across the Roche Pharma Division across units; productivity metrics development (ROI), analysis/performance tracking and goal setting; analysis of the Roche Group's R&D spend; external benchmarking.Support the development of the Group's 10yr Business Plan and various ad-hoc work for the CFO.Sustainability reporting on innovation for external indices (eg Dow Jones Sustainability Index, Access to Medicines Index etc).

Analysis and generation of insights based on benchmarking data for probability of success, cycle time/phase duration and cost, based on available external benchmarks (eg KMR and CMR) and internal historic data; in addition support of corporate planning assumptions. Lead development and use of portfolio analytics methodology and portfolio metrics, supporting R&D productivity analyses, value metrics and prioritization.

Lead Pipeline and Portfolio Planning for the later stage pipeline in the CNS and Metabolism areas. Support senior management's decision making with portfolio perspective and insight (across clinical phases), illustrating value, cost and risk for proposed options for phase II and III projects (NMEs and line extensions), as well as work with teams to communicate value/risk and alternatives/trade-offs clearly to management.

Facilitate the business planning process (molecule business plan) for all pipeline and life-cycle management projects, with primary focus from phase 1 entry to launch. Act as sparring partner and facilitator to the project team, and Project Director/VP, to make the strongest possible business plans, and help teams generate meaningful strategic options. Responsible for the Product Business Planning training program.

Project leader on strategy review projects, where one business issue/area is reviewed along with top management and key stakeholders, and that result in decisions such as closing/divesting projects. Analysis and coordination of M&A landscaping/transactions, and other strategic transactions. Coordination of the overall annual corporate strategy process, including project management, as well as strategic and analytical work to executive management.

Responsible for Portfolio Analysis in the New Product Planning function, 3 direct reports. Support the corporate portfolio prioritization across and between disease areas with appropriate portfolio analyses. Commercial assessment of in-licensing and business development opportunities: including TPP generation, market research, market assessment and forecasting, scenario generation - to support BD and M&A. Participate in the annual strategic planning process with scenario and what-if analyses. Project manager for implementing a new valuation system (from Enrich Consulting), including design, testing, rollout, and follow-up.

Responsible for project valuation (ENPVs) for part of the portfolio (both preclinical projects, as well as development projects). Mainly within haemostasis and cancer. Also involved in improving the basis for strategic decision making - by helping develop thinking in strategic (real) options, and challenge product business plans. Furthermore develop patient flow- and pharmacoepidemiological models for cancer and heamostasis.

Forecasting of pipeline products within diabetes and haemostasis (both for strategic analysis and for operational shorter-term demand planning). Development and implementation of a global diabetes patient forecasting stock-flow model (pharmaco-epidemiological model). Involved in designing and implementing a Global Sales Forecasting system in SAP; main role was in setting up the statistical part, but I was also a part of the roll-out team visiting all affiliates conducting change management and training.

• Lead developer of the Computable General Equilibrium model DREAM. • Analysis of economic policy (mainly fiscal and labor market policy), presented findings both to specialist and non-specialist audiences.• Development of a population forecast module used by the bureauConcurrent with doing a PhD in Economics at the University of Copenhagen

Controlling, managing budgeting process, support SAP implementation, various analytics for the senior leaders